Charles River, WuXi end merger

Charles River Laboratories International Inc. (NYSE:CRL) and fellow CRO WuXi PharmaTech Inc. (NYSE:WX) ended a deal under which Charles River agreed to acquire WuXi for $1.5 billion in cash and stock. The decision came after Charles River shareholders opposed the acquisition. WuXi will receive a $30 million breakup fee. ...